Literature DB >> 21115551

A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study.

E van der Kooi1, N B Klarenbeek, M Güler-Yüksel, P J S M Kerstens, P A H M van der Lubbe, M L Westedt, S ten Wolde, T W J Huizinga, B A C Dijkmans, C F Allaart.   

Abstract

OBJECTIVE: To assess the relationship between a decrease in disease activity score (DAS) and functional ability during 5 years of DAS-steered treatment in recent-onset rheumatoid arthritis (RA) patients, taking into account absolute DAS levels and follow-up duration.
METHODS: Data from the BeSt study were used, in which treatment was aimed at achieving DAS ≤2.4. The longitudinal relationship between 3-monthly measured DAS and health assessment questionnaire (HAQ) score was assessed using linear mixed modelling during 5 years of treatment, with DAS and HAQ 3 months earlier, change in DAS in last 3 months (delta DAS), time (log-transformed) and their interactions as determinants.
RESULTS: Predictors for HAQ were: previous DAS, delta DAS, ln time, the interaction previous DAS×delta DAS, and previous HAQ. The interaction ln time×delta DAS was non-significant, indicating that the association between delta DAS and HAQ was independent of follow-up duration. A decrease from a higher DAS was associated with a smaller HAQ decrease than for a similar decrease from a lower DAS, indicating a non-linear relationship between DAS and HAQ.
CONCLUSION: At any time during 5 years of follow-up, a decrease in DAS was associated with a better functional ability. The magnitude of HAQ improvement depends on the DAS decrease and on the absolute DAS level.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21115551     DOI: 10.1136/ard.2010.133132

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  6 in total

1.  Potential of the HAQ score as clinical indicator suggesting comprehensive multidisciplinary assessments: the Swedish TIRA cohort 8 years after diagnosis of RA.

Authors:  Ingrid Thyberg; Ö Dahlström; M Björk; P Arvidsson; M Thyberg
Journal:  Clin Rheumatol       Date:  2012-01-17       Impact factor: 2.980

2.  Cost-Effectiveness of Repository Corticotropin Injection versus Standard of Care for the Treatment of Active Rheumatoid Arthritis.

Authors:  Jas Bindra; Ishveen Chopra; John Niewoehner; Mary Panaccio; George J Wan
Journal:  Clinicoecon Outcomes Res       Date:  2021-05-06

3.  Interleukin-34 produced by human fibroblast-like synovial cells in rheumatoid arthritis supports osteoclastogenesis.

Authors:  Seung-Jun Hwang; Bongkun Choi; Soon-Suk Kang; Jae-Ho Chang; Yong-Gil Kim; Yeon-Ho Chung; Dong Hyun Sohn; Min Wook So; Chang-Keun Lee; William H Robinson; Eun-Ju Chang
Journal:  Arthritis Res Ther       Date:  2012-01-20       Impact factor: 5.156

4.  Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Tsutomu Takeuchi; Yoshiya Tanaka; Satoshi Soen; Hisashi Yamanaka; Toshiyuki Yoneda; Sakae Tanaka; Takaya Nitta; Naoki Okubo; Harry K Genant; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2019-04-29       Impact factor: 19.103

5.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103

6.  Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.

Authors:  Sytske Anne Bergstra; Otto Olivas; Gülşah Akdemir; Naghmeh Riyazi; Gerard Collée; Johannes H L M van Groenendael; Robert B M Landewé; Cornelia F Allaart
Journal:  Arthritis Res Ther       Date:  2017-09-30       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.